FDA clears gel that can stop bleeding in seconds

The latest stories trending on MedCity News.

Editor's Pick

Top Story FDA Clears Gel That Can Stop Bleeding In Seconds Cresilon snagged its second FDA clearance for human use. The FDA granted 510(k) clearance to Traumagel, the startup's gel that can stop bleeding in just seconds, for temporary external use to control moderate to severe bleeding. Sponsored 5 Health Reasons to Ditch Concrete Jungles for Countryside Presented by MedCity News & Impact Brands In an increasingly urbanized world, the allure of countryside living is growing stronger, especially when it comes to health and well-being. While cities offer numerous opportunities, rural areas provide unique health benefits that are hard to replicate in urban environments. Let's explore five compelling health reasons why trading skyscrapers for rolling hills might be the best decision for your overall wellness. Learn More. INVEST Digital Health: Fireside Chat with Dr. Eve Cunningham A highlight on September 18 at Pegasus Park, Dallas will be the Fireside Chat featuring Dr. Eve Cunningham, Group VP and Chief of Virtual Care and Digital Health at Providence.   See Full Conference Agenda: Agenda - MedCity INVEST (medcityinvestconference.com)    Secure You Spot Today

Featured News

Accelerating Claim Processing: Strategies to Shorten the Life of a Claim  These strategies and practices can significantly shorten the life cycle of claims, leading to quicker resolutions and improved financial outcomes. Digital Therapeutics Sector Sees Billing Codes as Key to Breaking Free of Reimbursement Rut Medicare's physician fee schedule includes billing codes for digital therapeutics for the first time. Stakeholders say these codes could help turn around reimbursement challenges weighing on the entire digital medicines sector. Report: MA Insurers Denied 3.4M Prior Authorization Requests in 2022 About 7.4% of prior authorization requests submitted to MA insurers were denied in 2022, according to a recent KFF report. Of these denials, only 9.9% were appealed. Three Ways Drug Pricing Should Work in a Functioning Market, But Isn't We can't wait for others to find a solution to high drug prices. It's clear what should happen in a functioning drug pricing market federally and in California, but it is not happening today.

Resources

MedCity FemFwd: The Lack of Research on Chronic Conditions Affecting Women In this episode, we're joined by Stacey Missmer, professor and associate chair for epidemiology and translational research at the University of Michigan. She discusses a report she recently co-authored that calls on the NIH to improve research on chronic conditions affecting women. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe